Ibnsina signs two drug-distribution contracts with Novo Nordisk
Ibnsina Pharma [ISPH.CA] announced that it has signed two contacts with Novo Nordisk, a leading manufacturer of insulin and haemophilia treatment with a 60% market share in insulin, to distribute over 20 stock-keeping units (SKUs) of its diabetes care, haemophilia and growth disorder products across Egypt. Ibnsina has invested EGP2mn in additional warehousing facilities for the distribution contract and allocated 28 specialised lorries to deliver Novo Nordisk’s cold-chain products. In addition, it has also passed Novo Nordisk’s due diligence and operational audit to meet international standards.
This website uses cookies to make the site work, to understand if the site is working well, how it is being used, to connect to social media sites (such as Facebook and Twitter) and to collect information useful to allow us and our partners to provide you with more relevant ads . Some cookies are essential to make the site work, but you can control how we use non-essential cookies at any time by clicking the “ON/OFF” button next to each category. For more information about the cookies used on this site, see Privacy Policy.
Decide which cookies you want to allow.
Strictly Necessary
These cookies are essential in order to enable you to move around our website and use its features, such as accessing secure areas of our website. Without these cookies, any services on our Site you wish to access cannot be provided.
Analytical/performance cookies
Visitors use our website, for instance which pages you go to most often, and if you get error messages from web pages.